In impaired glucose tolerance patients, administration of linagliptin during three months decreased glucose levels at 90 and 120 minutes after a 75-g oral dextrose load and area under the curve of glucose, meanwhile metformin just decreased insulin at 0 minutes.

The ability of metformin to enhance the cytotoxic profile of carboplatin in platinum resistant OVCAR3 ovarian cancer cells was evaluated alone and in the presence of the FAK inhibitor PF-5733228. Metformin significantly increased OVCAR3 sensitivity to both carboplatin and PF-573228.